Detalhe da pesquisa
1.
CXCR2 inhibition enables NASH-HCC immunotherapy.
Gut
; 2022 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35477863
2.
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Hepatology
; 74(5): 2652-2669, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34157147
3.
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
J Hepatol
; 75(4): 865-878, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33992698
4.
Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?
Br J Cancer
; 118(2): 248-257, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29123264
5.
Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?
J Hepatol
; 65(2): 305-13, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27132171
6.
Corrigendum to 'Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis' [J Hepatol 75 (2021) 865-878].
J Hepatol
; 75(6): 1515, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34627652
7.
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.
Nat Rev Gastroenterol Hepatol
; 20(8): 487-503, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36932227
8.
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.
Mol Cancer Ther
; 22(4): 485-498, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36780225
9.
Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma.
Clin Cancer Res
; 28(11): 2449-2460, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35302601
10.
Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma.
Clin Cancer Res
; 27(7): 1827-1829, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33472912
11.
Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma.
Clin Cancer Res
; 26(23): 6350-6361, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32873569
12.
Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.
J Clin Invest
; 130(1): 258-271, 2020 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31581151
13.
DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.
Clin Cancer Res
; 21(4): 925-33, 2015 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25480831
14.
Combination PARP and HDAC inhibition as a therapeutic strategy targeting liver cancer stem cells?
Chin Clin Oncol
; 5(5): 60, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27164859